Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to grant Novavax full approval – without restrictions -- by its April 1 target ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.